Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology

Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology

Background Local priming of the innate immune system with a Toll-like receptor (TLR)2/6 agonist may reduce morbidity and mortality associated with viral respiratory tract infections, particularly for the elderly and those with chronic diseases. The objectives of the present study were to understand...

Full description

Saved in:
Bibliographic Details
Main Authors: Francesca A. Mercuri, Scott White, Hayley A. McQuilten, Charlotte Lemech, Stephan Mynhardt, Rana Hari, Ping Zhang, Nicole Kruger, Grant McLachlan, Bruce E. Miller, Nicholas P. West, Ruth Tal-Singer, Christophe Demaison
Format: Article
Language:English
Published: European Respiratory Society 2024-12-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/10/6/00199-2024.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items